ImmunoPrecise Antibodies’ (IPA) Buy Rating Reaffirmed at HC Wainwright

ImmunoPrecise Antibodies (NASDAQ:IPA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $5.00 price target on the stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price objective on shares of ImmunoPrecise Antibodies in a research note on Tuesday, April 1st.

ImmunoPrecise Antibodies Stock Performance

NASDAQ:IPA opened at $0.43 on Friday. ImmunoPrecise Antibodies has a 1 year low of $0.27 and a 1 year high of $1.39. The business has a fifty day simple moving average of $0.41 and a two-hundred day simple moving average of $0.46. The company has a market capitalization of $13.40 million, a P/E ratio of -0.55 and a beta of -0.02. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85.

ImmunoPrecise Antibodies (NASDAQ:IPA) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. The firm had revenue of $4.23 million during the quarter, compared to analyst estimates of $6.59 million. On average, analysts expect that ImmunoPrecise Antibodies will post -0.27 earnings per share for the current year.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.